NCT06144060尚未招募2 期
A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 126
- 主要终点
- Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)
研究概览
简要总结
The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide a written informed consent before the study, fully understand the study and be able to complete the study according to the protocol;
- •Male and female, 18 to 75 years of age, inclusive;
- •Judged by the investigator, clinical diagnosis with cUTI or AP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics;
- •Urine specimen with evidence of pyuria；
- •Have urine culture specimen obtained within 48 hours prior to randomization;
- •Women of childbearing potential must have a negative serum pregnancy test before first dose, must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of contraception, with no plan of birth, sperm/ovum donation from the time of signed ICF till 14 days after end of treatment.
排除标准
- •History of significant hypersensitivity or allergic reaction to any β-lactam, or any β-lactamase inhibitors;
- •Known history of immune deficiency disease or receive immunocompromising treatment;
- •Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable condition or uncontrolled;
- •Known or suspected central nervous system disorder or other factors that may predispose to seizures or lower the seizures onset threshold;
- •Presence of any known or suspected disease or condition that, in the opinion of the Investigator, may confound the assessment of efficacy;
- •Uncomplicated lower urinary tract infection;
- •Suspected or confirmed urinary tract symptoms caused by acute/chronic prostatitis, orchitis, epididymitis or sexually transmitted diseases as determined by medical history and/or physical examination;
- •Patients diagnosed malignant tumors prior to randomization and currently with;
- •Systemic antimicrobial therapy other than the investigational drug need to be used during the study period, with the exception of topical or single oral dose of antifungal treatment
- •Urinary tract surgery prior to the randomization or urinary tract surgery planned during the study period;
- •Receipt of potentially effective systemic antibacterial therapy for a continuous duration of >24 hours during the previous 72 hours prior to the randomization;
- •History of pelvis or urinary tract trauma prior to the randomization;
- •Patients had severe trauma or received major surgery prior to the randomization, or surgery planned during the study period;
- •Impairment of renal function with estimated glomerular filtration rate <15 mL/min (calculated by the Modification of Diet in Renal Disease study equation);
- •Laboratory abnormalities in baseline specimens obtained at screening;
- •A QTcF interval prolongation at screening or abnormalities with clinical significance and may cause obvious safety risk to the subjects;
- •Known urine culture with at least one Gram-Negative uropathogen at ≥105 colony-forming units(CFU)/mL unsusceptible to Imipenem and Cilastatin Sodium, or only identify Gram-positive uropathogen, or confirmed fungal urinary tract infection with ≥103CFU/mL;
- •Indwelling catheter or urinary tract instrument, in the opinion of the Investigator, incapable of removal during the study period;
- •Likely to require the use of antibiotic for cUTI or AP prophylaxis after treatment;
- •Suspected of sepsis, producing life-threatening organ dysfunction;
- •Estimated survival within 6 weeks or rapidly progressive or end stage disease with high mortality rate;
- •Drug abuse prior to the randomization;
- •Participated in, any other clinical study involving the administration of active investigational or experimental medication prior to the randomization, or 5 half-lives, whichever is longer, prior to Screening;
- •In the judgment of the Investigator, other reasons unsuitable for study.
研究组 & 干预措施
Treatment group A：HRS-8427
Experimental
干预措施: HRS -8427 (Drug)
Treatment group B：HRS-8427
Experimental
干预措施: HRS -8427 (Drug)
Imipenem and Cilastatin Sodium
Active Comparator
干预措施: Imipenem and Cilastatin Sodium (Drug)
结局指标
主要结局
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)
时间窗: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)
次要结局
- Percentage of Participants With Microbiological Eradication at EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen(EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen)
- Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen(EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen)
- Percentage of Participants With Microbiological Eradication at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）(EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）)
- Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment（EA）、End of Treatment（EOT）and Late Follow-Up (LFU)(EA : Day 4、EOT: Day 7 to Day 14、LFU：Day 21 to Day 28)
- Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）(EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）)
研究者
相似试验
已完成
2 期
A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisPatients With Candidemia and/or Invasive CandidiasisNCT06194201Fujian Shengdi Pharmaceutical Co., Ltd.61
招募中
3 期
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisComplicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)NCT06569056Jiangsu HengRui Medicine Co., Ltd.578
已完成
1 期
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications DevicesModerate-to-Severe Plaque PsoriasisNCT06182384Suzhou Suncadia Biopharmaceuticals Co., Ltd.46
已完成
1 期
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different SitesType 2 DiabetesNCT06086912Jiangsu HengRui Medicine Co., Ltd.24
招募中
2 期
The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric InfarctionSevere Cerebral Edema Following Large Hemispheric InfarctionNCT06732648Beijing Suncadia Pharmaceuticals Co., Ltd725